Andrew Emerson compensation by year
IDEXX Laboratories Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $531,146 |
| Bonus | $0 |
| Stock awards | $949,864 |
| Option awards | $949,941 |
| Non-equity incentive | $577,500 |
| Pension and deferred compensation | $0 |
| All other | $24,620 |
| Total | $3,033,071 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IDEXX Laboratories Inc DEF 14A filed March 27, 2026, accession 0000874716-26-000064, and prior-year filings. Open the filing on EDGAR.
How this page was built: the IDEXX Laboratories Inc filed document, accession 0000874716-26-000064. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 2,066 | $1,397,711 | — |
| RSU | 1,033 | $698,855 | — |
| RSU | 188 | $127,188 | — |
| PSU | 167 | $112,981 | — |
| RSU | 125 | $84,566 | — |
| Option | 4,600 | — | $459.76 |
| Option | 460 | — | $497.43 |
Per the Outstanding Equity Awards at Fiscal Year-End table in IDEXX Laboratories Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed March 27, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-20 | Exercise or conversion | — | 265 | $178.26 | 4,507.44 |
| 2026-08-20 | Tax withholding | — | 86 | $0.00 | 4,421.44 |
| 2026-08-20 | Exercise or conversion derivative | — | 265 | — | 925 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments IDEXX Laboratories discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Disability | $0 | $2,941,859 | $1,320,000 | $4,261,859 |
| Retirement | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $1,619,924 | $2,941,859 | $42,423 | $5,041,706 |
| Involuntary termination without cause | $0 | $0 | $0 | $0 |
| Death | $0 | $2,941,859 | $1,320,000 | $4,261,859 |
Per the Potential Payments Upon Termination or Change in Control table in IDEXX Laboratories Inc's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
IDEXX Laboratories’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jonathan Mazelsky | President and Chief Executive Officer | $14,580,122 |
| Michael Lane | Executive Vice President and General Manager, CAG Diagnostics Business Unit | $4,019,416 |
| Tina Hunt | Executive Vice President, Global Strategy and Commercial | $3,945,293 |
| Martin Smith | Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | $3,944,534 |
| Andrew Emerson · this page | Executive Vice President, Chief Financial Officer and Treasurer | $3,033,071 |
| Brian McKeon | Former Executive Vice President, Chief Financial Officer and Treasurer | $351,680 |
Andrew Emerson's compensation dossier, IDEXX Laboratories
You have read Andrew Emerson's totals and holdings. The dossier adds each equity grant IDEXX Laboratories disclosed for Andrew Emerson and IDEXX Laboratories's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full IDEXX Laboratories compensation record
free company briefThis page is one person within IDEXX Laboratories's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the IDEXX Laboratories proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order IDEXX Laboratories's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IDEXX Laboratories's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IDXX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.